CD274 and neoplasm: At variance to early TNBC, a clinical benefit was observed for metastatic TNBC patients expressing PD-L1 on tumor cells (Cortes et al. 2020; Mittendorf et al. 2020; Schmid et al. 2020a, b, c; Schmid et al. 2021).